Stock Market Reviews

MDXH (MDxHealth SA) News

Get the latest news, insights, and market updates on MDXH (MDxHealth SA). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne
  Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne Year-over-year Q2 revenues increased by 20% to $26.6 millionAdjusted EBITDA profitability of $1.4 million for Q2 Agreement to acquire ExoDx Business from Bio-Techne for $15 million in cash and stock over 5 years; acquisition expected to accelerate revenue growth and be accretive to adjusted EBITDA Conference call with Q&A today at
  Aug 5, 2025 - $MDXH
• Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change
  IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles
  Jul 3, 2025 - $MDXH
• MDxHealth SA (MDXH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Operational ...
  MDxHealth SA (MDXH) reports a 22% revenue increase and improved gross margins, while maintaining a disciplined approach to growth opportunities.
  May 15, 2025 - $MDXH
• MDxHealth SA (MDXH) Reports Q1 Loss, Tops Revenue Estimates
  MDxHealth SA (MDXH) delivered earnings and revenue surprises of -46.15% and 0.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
  May 14, 2025 - $MDXH
• MDxHealth Reports Q1-2025 Results
  Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: “mdxhealth deliver
  May 14, 2025 - $MDXH
• Mdxhealth to Release First Quarter 2025 Financial Results on May 14
  Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title:Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief
  Apr 30, 2025 - $MDXH
• Down -15.22% in 4 Weeks, Here's Why You Should You Buy the Dip in MDxHealth SA (MDXH)
  MDxHealth SA (MDXH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
  Mar 6, 2025 - $MDXH
• MDxHealth SA (MDXH) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Margin Challenges
  MDxHealth SA (MDXH) reports a 28% revenue increase and significant test volume growth, while navigating margin pressures and strategic growth opportunities.
  Feb 27, 2025 - $MDXH
• MDxHealth SA (MDXH) Reports Q4 Loss, Tops Revenue Estimates
  MDxHealth SA (MDXH) delivered earnings and revenue surprises of 30% and 7.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
  Feb 26, 2025 - $MDXH
• Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results
  Fourth quarter revenue growth of 28% to $24.7 million2024 revenue growth of 28% to $90.0 million68% improvement in adjusted EBITDA in fourth quarterConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Michael K. McGarrity, CEO o
  Feb 26, 2025 - $MDXH